Fixed-Dose-Rate Gemcitabine in Combination with Oxaliplatin in Patients with Metastatic Pancreatic Cancer Refractory to Standard-Dose-Rate Gemcitabine: A Single-Institute Study

Publisher： Karger

E-ISSN： 1423-0232|76|5|333-337

ISSN： 0030-2414

Source： Oncology, Vol.76, Iss.5, 2009-03, pp. : 333-337

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Trial of Fixed-Dose Rate Gemcitabine plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients

By  

Oncology, Vol. 82, Iss. 2, 2012-02 ,pp. : 75-82

Karger

Access to resources Recommend Favorite

Gemcitabine and Oxaliplatin Combination Chemotherapy for Patients with Refractory Pancreatic Cancer

By  

Oncology, Vol. 80, Iss. 1-2, 2011-06 ,pp. : 97-101

Karger

Access to resources Recommend Favorite

Phase I Dose-Finding Study of Vandetanib in Combination with Gemcitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma

By  

Oncology, Vol. 81, Iss. 1, 2011-09 ,pp. : 50-54

Karger

Access to resources Recommend Favorite

Chemoradiotherapy in Patients with Pancreatic Carcinoma: Phase-I Study with a Fixed Radiation Dose and Escalating Doses of Weekly Gemcitabine

By  

Pancreatology, Vol. 6, Iss. 1-2, 2006-04 ,pp. : 109-116

Karger

Access to resources Recommend Favorite

A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 159-163

Karger

Access to resources Recommend Favorite